Endo USA, INC., a Mallinckrodt-endo Company
Issues related to pharmaceutical drugs
Based in PA
🤖
AI Overview
With $1.0M in lobbying spend across 46 quarterly filings, Endo USA, INC., a Mallinckrodt-endo Company is a significant lobbying presence. Their lobbying covers 4 issue areas. Active from 2018 to 2025.
$1.0M
Total Spend
8
Years Active
1
Firms Hired
10
Lobbyists Deployed
4
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2018 | $200K |
| 2019 | $80K |
| 2020 | $160K |
| 2021 | $160K |
| 2022 | $160K |
| 2023 | $80K |
| 2024 | $100K |
| 2025 | $80K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Pharmacy, Health Issues, Medicare/Medicaid, Trade
- •Implementation of the Drug Quality and Security Act
- •DQSA implementation/drug compounding
- •Pharmaceutical issues
- •Issues related to drug compounding and the pharmaceutical industry
Related Analysis
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
The 2025 Tariff Panic
As tariffs return, lobbying on trade surges.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.